Acceder

Bibliografías temáticas / Liver radioembolization

Literatura académica sobre el tema "Liver radioembolization"

Autor: Grafiati

Publicado: 29 de junio de 2022

Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros

Elija tipo de fuente:

Consulte las listas temáticas de artículos, libros, tesis, actas de conferencias y otras fuentes académicas sobre el tema "Liver radioembolization".

Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.

También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.

Índice

Artículos de revistas
Tesis
Libros
Capítulos de libros
Actas de conferencias

Artículos de revistas sobre el tema "Liver radioembolization":

1

Carrion-Martin, L., J. Orcajo Rincón, A. Rotger, M. Gonzalez-Leyte, L. Márquez Pérez, M. Echenagusia y A. Matilla. "Radioembolization in liver tumors". Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) 38, n.º 6 (noviembre de 2019): 370–81. http://dx.doi.org/10.1016/j.remnie.2019.06.005.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

2

Braat, Manon N. G. J. A., Karel J. van Erpecum, Bernard A. Zonnenberg, Maurice A. J. van den Bosch y Marnix G. E. H. Lam. "Radioembolization-induced liver disease". European Journal of Gastroenterology & Hepatology 29, n.º 2 (febrero de 2017): 144–52. http://dx.doi.org/10.1097/meg.0000000000000772.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

3

Braat, A. J. A. T., H. Ahmadzadehfar, S. C. Kappadath, C. L. Stothers, A. Frilling, C. M. Deroose, P. Flamen et al. "Radioembolization with 90Y Resin Microspheres of Neuroendocrine Liver Metastases After Initial Peptide Receptor Radionuclide Therapy". CardioVascular and Interventional Radiology 43, n.º 2 (23 de octubre de 2019): 246–53. http://dx.doi.org/10.1007/s00270-019-02350-2.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Resumen

Abstract Purpose Peptide receptor radionuclide therapy (PRRT) and radioembolization are increasingly used in neuroendocrine neoplasms patients. However, concerns have been raised on cumulative hepatotoxicity. The aim of this sub-analysis was to investigate hepatotoxicity of yttrium-90 resin microspheres radioembolization in patients who were previously treated with PRRT. Methods Patients treated with radioembolization after systemic radionuclide treatment were retrospectively analysed. Imaging response according to response evaluation criteria in solid tumours (RECIST) v1.1 and clinical response after 3 months were collected. Clinical, biochemical and haematological toxicities according to common terminology criteria for adverse events (CTCAE) v4.03 were also collected. Specifics on prior PRRT, subsequent radioembolization treatments, treatments after radioembolization and overall survival (OS) were collected. Results Forty-four patients were included, who underwent a total of 58 radioembolization procedures, of which 55% whole liver treatments, at a median of 353 days after prior PRRT. According to RECIST 1.1, an objective response rate of 16% and disease control rate of 91% were found after 3 months. Clinical response was seen in 65% (15/23) of symptomatic patients after 3 months. Within 3 months, clinical toxicities occurred in 26%. Biochemical and haematological toxicities CTCAE grade 3–4 occurred in ≤ 10%, apart from lymphocytopenia (42%). Radioembolization-related complications occurred in 5% and fatal radioembolization-induced liver disease in 2% (one patient). A median OS of 3.5 years [95% confidence interval 1.8–5.1 years] after radioembolization for the entire study population was found. Conclusion Radioembolization after systemic radionuclide treatments is safe, and the occurrence of radioembolization-induced liver disease is rare. Level of Evidence 4, case series.

4

Birgin, Emrullah, Erik Rasbach, Steffen Seyfried, Nils Rathmann, Steffen J. Diehl, Stefan O. Schoenberg, Christoph Reissfelder y Nuh N. Rahbari. "Contralateral Liver Hypertrophy and Oncological Outcome Following Radioembolization with 90Y-Microspheres: A Systematic Review". Cancers 12, n.º 2 (27 de enero de 2020): 294. http://dx.doi.org/10.3390/cancers12020294.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Resumen

Radioembolization with 90Y-microspheres has been reported to induce contralateral liver hypertrophy with simultaneous ipsilateral control of tumor growth. The aim of the present systematic review was to summarize the evidence of contralateral liver hypertrophy and oncological outcome following unilateral treatment with radioembolization. A systematic literature search using the MEDLINE, EMBASE, and Cochrane libraries for studies published between 2008 and 2020 was performed. A total of 16 studies, comprising 602 patients, were included. The median kinetic growth rate per week of the contralateral liver lobe was 0.7% and declined slightly over time. The local tumor control was 84%. Surgical resection after radioembolization was carried out in 109 out of 362 patients (30%). Although the available data suggest that radioembolization prior to major hepatectomy is safe with a promising oncological outcome, the definitive role of radioembolization requires assessment within controlled clinical trials.

5

Facciorusso, Antonio, Irene Bargellini, Marina Cela, Ivan Cincione y Rodolfo Sacco. "Comparison between Y90 Radioembolization Plus Sorafenib and Y90 Radioembolization alone in the Treatment of Hepatocellular Carcinoma: A Propensity Score Analysis". Cancers 12, n.º 4 (7 de abril de 2020): 897. http://dx.doi.org/10.3390/cancers12040897.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Resumen

Background: Adjuvant sorafenib may enhance the efficacy of transarterial radioembolization with yttrium-90 in hepatocellular carcinoma patients. The aim of this study is to assess the efficacy and safety of radioembolization plus sorafenib in comparison to radioembolization alone. Methods: Out of 175 hepatocellular carcinoma (HCC) patients treated with radioembolization between 2011 and 2018, after propensity score matching, two groups were compared: a group of 45 patients that underwent radioembolization while being on sorafenib (Group 1) and a second group of 90 patients that underwent radioembolization alone (Group 2). Results: Baseline characteristics of the two groups were well balanced concerning liver function and tumor burden. No significant differences in survival outcomes were identified (median overall survival 10 vs. 10 months; p = 0.711), median progression-free survival 6 vs. 7 months (p = 0.992) in Group 1 and Group 2). The objective response rate in Group 1 vs. Group 2 was 45.5% vs. 42.8% (p = 1) according to mRECIST. No differences in toxicity nor in liver decompensation rates were registered. Conclusions: The association of sorafenib does not prolong survival nor delay progression in patients treated with radioembolization. Liver toxicity does not differ among the two therapeutic schemes.

6

De Souza, Andre, Kevin Pelham Daly, James Yoo y Muhammad Wasif Saif. "Safety and Efficacy of Combined Yttrium 90 Resin Radioembolization with Aflibercept and FOLFIRI in a Patient with Metastatic Colorectal Cancer". Case Reports in Oncological Medicine 2015 (2015): 1–6. http://dx.doi.org/10.1155/2015/461823.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Resumen

Background. When associated with isolated four or fewer liver foci, metastatic colorectal cancer is amenable to surgical resection. Alternative therapeutic methods for isolated liver metastases include radioembolization with yttrium 90 (Y90) and transarterial chemoembolization (TACE). We present here a case of a patient with two sites of liver metastatic disease from colorectal cancer who underwent Y90 radioembolization combined with aflibercept and FOLFIRI.Case Report. A 56-year-old female with history of bilateral breast cancer and metastatic colon cancer with prior hemicolectomy and 4 previous chemotherapy regimens developed liver metastasis. She was started on aflibercept and FOLFIRI and concurrently underwent two treatments of radioembolization with Y90, initially targeting the largest right lobe tumor, and then a subsequent treatment targeting the smaller left lobe tumor with retreatment of the right lobe tumor. Her liver metastases exhibited partial response on imaging utilizing the modified RECIST criteria. Interestingly, the patient CEA levels decreased after the procedure.Discussion. This is the first reported case of a patient managed with radioembolization with Y90 combined with aflibercept, an anti-VEGF treatment, and FOLFIRI. An ongoing randomized clinical trial aims to define the role of combined targeted therapy and chemotherapy with radioembolization with Y90.

7

Elsayed, Mohammad, Robert M. Ermentrout, Ila Sethi, Zachary L. Bercu, James R. Galt, Morgan Whitmore, David C. Brandon, David M. Schuster y Nima Kokabi. "Incidence of Radioembolization-Induced Liver Disease and Liver Toxicity Following Repeat 90Y-Radioembolization". Clinical Nuclear Medicine 45, n.º 2 (febrero de 2020): 100–104. http://dx.doi.org/10.1097/rlu.0000000000002828.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

8

Lebedev, Dmitry Petrovich, Dmitry Nikolaevich Panchenkov, Yuri Viktorovich Ivanov, Dmitry Anatolievich Astakhov y Elena Alexandrovna Zvezdkina. "RADIOEMBOLIZATION AS A METHOD FOR THE TREATMENT OF UNRESECTABLE PRIMARY AND METASTATIC LIVER CANCER (LITERATURE REVIEW)". Journal of Experimental and Clinical Surgery 13, n.º 1 (25 de febrero de 2020): 61–69. http://dx.doi.org/10.18499/2070-478x-2020-13-1-61-69.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Resumen

A review of the literature on one of the methods of treatment of unresectable primary and metastatic liver cancer, namely radio embolization, is presented. A detailed description of the procedure for performing radioembolization of the liver vessels, possible complications, indications and contraindications to this method, lists the necessary equipment and tools. Particular attention is paid to the description of the microspheres used in radioembolization. A modern review of clinical studies, including those still unfinished, devoted to the method of radioembolization with unresectable primary and metastatic liver cancer is given.

9

Laidlaw, Grace L. y Guy E. Johnson. "Recognizing and Managing Adverse Events in Y-90 Radioembolization". Seminars in Interventional Radiology 38, n.º 04 (octubre de 2021): 453–59. http://dx.doi.org/10.1055/s-0041-1735617.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Resumen

AbstractTransarterial radioembolization using yttrium-90 (Y-90) microspheres is an important therapy in the management of unresectable primary liver tumors or hepatic metastases. While radioembolization is generally well-tolerated, it is not free from adverse events, and familiarity with the prevention and treatment of radioembolization-specific complications is an important component of patient care. This article aims to review radioembolization-specific toxicities stratified by hepatic, extrahepatic, and systemic effects, with a focus on preventing and mitigating radioembolization-induced morbidity.

10

Kiszka, Joanna y Bożenna Karczmarek-Borowska. "Radioembolization treatment for liver metastases". Współczesna Onkologia 21, n.º 4 (2017): 274–78. http://dx.doi.org/10.5114/wo.2017.72153.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Más fuentes

Tesis sobre el tema "Liver radioembolization":

1

Levillain, Hugo. "Prediction and improvement of radioembolization outcome using personalised treatment and dosimetry". Doctoral thesis, Universite Libre de Bruxelles, 2021. https://dipot.ulb.ac.be/dspace/bitstream/2013/320561/3/PhDTM.docx.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Resumen

Radioembolization (also called selective internal radiation therapy, SIRT) with yttrium-90 (90Y)-loaded microspheres has been broadly adopted as a locoregional therapy for primary and metastatic liver cancers. Although radioembolization is a well-established therapy, efforts to personalise and refine the planning and administration of therapy are ongoing. The ability to accurately predict, plan and deliver optimal doses to tumour and non-tumour tissues, including final validation of dose distribution, is essential for successful radiotherapy. Determining the true dose absorbed by tissue compartments is the primary way to safely individualise therapy for maximal response while respecting normal tissue tolerances. The overarching objective of this work was to expand our knowledge of dosimetry in 90Y-resin-microsphere radioembolization, with the ultimate goal of improving the clinical outcomes in our patients. Initially we sought to identify the patient- and treatment-related variables that predict radioembolization outcome in patients with intrahepatic cholangiocarcinoma (Chapter 2). Then, as a step toward personalised radioembolization in liver metastases from colorectal cancer patients, we evaluated the relationship between radioembolization real absorbed dose, as determined by 90Y positron emission tomography, and outcome (lesion-based and patient-based) (Chapter 3). In the work described in Chapter 4, we compared predictive (simulated) and post-treatment (real) dosimetry in liver metastases from colorectal cancer patients to pursue radioembolization personalisation. Finally, based on experience accumulated in previous studies and advances reported in the literature, we generated state-of-the-art recommendations to assist practitioners in performing personalised radioembolization with 90Y-resin microspheres in patients with primary and metastatic liver tumours (Chapter 5).
Doctorat en Sciences biomédicales et pharmaceutiques (Médecine)
info:eu-repo/semantics/nonPublished

2

Hammami, Houda. "Guidance of radioembolization procedures in the context of interventional oncology". Thesis, Rennes 1, 2021. http://www.theses.fr/2021REN1S121.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Resumen

La radioembolisation est une intervention mini-invasive réalisée pour traiter le cancer du foie en administrant des microsphères radioactives. Afin d'optimiser les résultats du traitement, la procédure est réalisée en deux sessions : une intervention de prétraitement, principalement réalisée pour localiser le site d'injection, évaluer la distribution et effectuer une évaluation dosimétrique, et une intervention de traitement réalisée pour injecter la dose appropriée de microsphères radioactives dans le site d'injection localisé. En raison la complexité de la vascularisation hépatique, les radiologues interventionnels manipulent soigneusement le cathéter, lors des deux interventions, sous guidage radiographique et recourent à l'injection de produit de contraste afin de visualiser les vaisseaux. Dans cette thèse, nous proposons une nouvelle stratégie de guidage qui promet une simplification et une précision de la navigation du cathéter lors des deux interventions. Le système de navigation proposé traite les images préopératoires et peropératoires pour réaliser une fusion d'images grâce à une technique de recalage rigide. Cette approche est conçue pour 1) aider l'accès au tronc cœliaque, 2) aider l'accès au site d'injection et 3) reproduire le site d'injection lors de l'intervention de traitement. Sachant que le foie subit un déplacement lié au mouvement respiratoire, nous proposons également une approche qui permet d'obtenir une superposition dynamique des vaisseaux 3D projetés sur la fluoroscopie
Radioembolization is a minimally-invasive intervention performed to treat liver cancer by administering radioactive microspheres. In order to optimize radioembolization outcomes, the procedure is carried out in two sessions: pretreatment assessment intervention, mainly performed to locate the injection site, assess microspheres distribution and perform dosimetry evaluation, and treatment intervention performed to inject the estimated proper dose of radioactive microspheres in the located injection site. Due to the hepatic vasculature complexity, interventional radiologists carefully manipulate the catheter, during the two interventions, under X-Ray image guidance and resort to contrast media injection in order to highlight vessels. In this thesis, we propose a novel guidance strategy that promises a simplification and accuracy of the catheter navigation during the pretreatment assessment, as well as during the treatment interventions. The proposed navigation system processes pre- and intraoperative images to achieve intraoperative image fusion through a rigid registration technique. This approach is designed to 1) assist the celiac trunk access, 2) assist the injection site access and 3) automatically reproduce the injection site during the proper intervention. Knowing that the liver undergoes a motion induced by the breathing, we also propose an approach that allows obtaining a dynamic overlay of the projected 3D vessels onto fluoroscopy

3

Vouche, Michael. "Radiation Segmentectomy, Radiation Lobectomy and Response Assessment after 90Yttrium Radioembolization for Hepatocellular carcinoma: Imaging and Clinical Implications". Doctoral thesis, Universite Libre de Bruxelles, 2017. http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/241979.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Resumen

Hepatocellular carcinoma is a primary liver cancer.Among treatment options for hepatocellular carcinoma, Yttrium-90 radioembolization is a promising transarterial therapy.This thesis investigates potential clinical applications of radioembolization in the treatment of the hepatocellular carcinoma (techniques of radiation segmentectomy and radiation lobectomy), and adress the problematic of the response Assessment after radioembolization.
Doctorat en Sciences médicales (Médecine)
info:eu-repo/semantics/nonPublished

4

Ferreira, Bárbara Mendes. "Radioembolização de metástases hepáticas do carcinoma colorretal". Master's thesis, 2021. http://hdl.handle.net/10400.6/11316.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Resumen

Introdução: O papel da radioembolização (RE) em metástases hepáticas do carcinoma colorretal (mhCCR) permanece indefinido. Esta investigação pretende avaliar os resultados e possíveis fatores de prognóstico da RE nestes doentes. Metodologia: Uma análise retrospetiva foi realizada a todos os doentes com mhCCR que foram intervencionados com uma RE no Instituto Português de Oncologia do Porto, desde janeiro de 2011 a março de 2020. A sobrevida a um ano foi determinada pelo método de Kaplan-Meier e os possíveis fatores de prognóstico foram avaliados usando os testes logRank, Qui-quadrado, de Fisher, Mann-Whitney e teste-t para amostras independentes. Resultados: Trinta pacientes foram avaliados. A idade média foi de 61,5 anos e a maioria dos doentes eram do sexo masculino (63,3%). A dor abdominal foi a complicação mais frequente (40%). O sucesso da RE foi observado em 50% dos casos. Um estádio inferior ou igual a três, níveis inferiores a 20 ng/mL de CEA ao diagnóstico, um tempo livre de metastização mais longo e a ausência de invasão vascular ou linfática ao diagnóstico estão significativamente associados ao sucesso da RE (valores P de <0,001, 0,035, 0,036, 0,028 e 0,020, respetivamente). A sobrevida a um ano de pacientes com ou sem sucesso na RE foi de 9,4 (IC 95%, 1,8-17,1) e 8,9 meses (IC 95%, 7,5-10,2), respetivamente. Conclusão: Vários fatores aumentam a probabilidade de obter uma RE com sucesso. Foi considerada uma terapêutica bem-tolerada, com a maioria das complicações facilmente geridas. Ainda assim, são necessários mais estudos, com amostras maiores, para avaliar a validade da RE.
Introduction: The role of radioembolization (RE) in liver dominant metastatic colorectal cancer (lmCRC) is unclear. This research aims to assess the prognostic factors and outcomes of RE in these patients. Methodology: A retrospective analysis of all patients with lmCRC who underwent RE in Instituto Português de Oncologia do Porto, from January 2011 to March 2020, was performed. The one-year survival was evaluated with the Kaplan-Meier method and potential prognostic factors were analyzed using the log-rank test, Mann-Whitney test, chisquare test, Fisher’s test, and t-test for independent samples. Results: Thirty patients were analyzed. The median age was 61,5 years and most patients were male (63,3%). There was a low complication rate. Successful RE was observed in 50% of the cases. Lower cancer stage, CEA levels at diagnosis lower than 20ng/mL, more than one year between diagnosis of CRC and the emergence of liver metastases, absence of vascular or lymphatic invasion at the moment of diagnosis were significantly associated with a successful RE (P values of <0,001, 0,035, 0,036, 0,028 and 0,020, respectively). The one-year survival of patients with and without successful RE was 9,4 months (CI 95%, 1,8- 17,1) and 8,9 months (CI 95%, 7,5-10,2), respectively. Conclusion: Several factors increase the likelihood of achieving a successful RE. The RE was considered a well-tolerated procedure, with easily managed complications and a low complication rate. However, more studies with larger cohorts are needed to validate this procedure.

5

Μουντρής, Κωνσταντίνος. "Ακτινοεμβολισμός ήπατος με μικροσφαιρίδια Υ-90 : Διερεύνηση της μεθόδου και βελτιστοποίηση με χρήση εξομοιώσεων Monte Carlo". Thesis, 2014. http://hdl.handle.net/10889/8152.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Resumen

Διευρεύνηση της μεθόδου του ακτινοεμβολισμού με μικροσφαιρίδια Υ-90 για τη αντιμετώπιση ηπατικών όγκων. Βελτίωση της image-based δοσιμετρίας προτείνοντας PET ιχνηθέτες.
Investigation of the method of radioembolization with Y90 microspheres for the treatment of liver malignancies. Improvement of the image-based dosimetry proposing the use of PET tracers.

Libros sobre el tema "Liver radioembolization":

1

Bilbao, José I. y Maximilian F. Reiser, eds. Liver Radioembolization with 90Y Microspheres. Berlin, Heidelberg: Springer Berlin Heidelberg, 2008. http://dx.doi.org/10.1007/978-3-540-35423-9.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

2

Bilbao, José Ignacio y Maximilian F. Reiser, eds. Liver Radioembolization with 90Y Microspheres. Berlin, Heidelberg: Springer Berlin Heidelberg, 2014. http://dx.doi.org/10.1007/978-3-642-36473-0.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

3

Bilbao, José I. Liver Radioembolization with 90Y Microspheres. Berlin, Heidelberg: Springer-Verlag Berlin Heidelberg, 2008.

Buscar texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

4

Reiser, Maximilian F. y José Ignacio Bilbao. Liver Radioembolization with 90Y Microspheres. Springer, 2014.

Buscar texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

5

Reiser, Maximilian F. y José Ignacio Bilbao. Liver Radioembolization with 90Y Microspheres. Springer, 2016.

Buscar texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

6

Bradley, Yong, Alexander S. Pasciak y J. Mark McKinney. Handbook of Radioembolization: Physics, Biology, Nuclear Medicine, and Imaging. Taylor & Francis Group, 2016.

Buscar texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Capítulos de libros sobre el tema "Liver radioembolization":

1

Sangro, Bruno, Mercedes Iñarrairaegui y Andrew S. Kennedy. "Radioembolization-Induced Liver Disease". En Liver Radioembolization with 90Y Microspheres, 177–85. Berlin, Heidelberg: Springer Berlin Heidelberg, 2013. http://dx.doi.org/10.1007/174_2013_817.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

2

Martínez-Ortega, Patricia, Fernando Pardo y Bruno Sangro. "Surgical Treatment and Radioembolization". En Liver Radioembolization with 90Y Microspheres, 167–70. Berlin, Heidelberg: Springer Berlin Heidelberg, 2013. http://dx.doi.org/10.1007/174_2013_947.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

3

Salem, Riad, Saad Ibrahim, Bassel Atassi y Robert J. Lewandowski. "Future Directions in Radioembolization". En Liver Radioembolization with 90Y Microspheres, 147–56. Berlin, Heidelberg: Springer Berlin Heidelberg, 2008. http://dx.doi.org/10.1007/978-3-540-35423-9_15.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

4

Kutlu, Ramazan, Sinan Karatoprak y Müge Otlu Karadağ. "Transarterial Radioembolization in Hepatocellular Carcinoma". En Liver Cancer in the Middle East, 137–69. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-78737-0_9.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

5

Shah, Rajesh P. y Daniel Y. Sze. "Radioembolization: Identifying and Managing Anatomic Variants". En Liver Radioembolization with 90Y Microspheres, 41–52. Berlin, Heidelberg: Springer Berlin Heidelberg, 2013. http://dx.doi.org/10.1007/174_2013_886.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

6

Salem, Riad, Robert J. Lewandowski, Robert K. Ryu, Kent Sato y Antonio Martinez de la Cuesta. "Radioembolization : Identifying and Managing Anatomic Variants". En Liver Radioembolization with 90Y Microspheres, 43–50. Berlin, Heidelberg: Springer Berlin Heidelberg, 2008. http://dx.doi.org/10.1007/978-3-540-35423-9_5.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

7

Trumm, C., R. T. Hoffmann, T. F. Jakobs y M. F. Reiser. "Regulations and Requirements of Hospitals Performing Radioembolization". En Liver Radioembolization with 90Y Microspheres, 11–14. Berlin, Heidelberg: Springer Berlin Heidelberg, 2013. http://dx.doi.org/10.1007/174_2013_809.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

8

Zech, Christoph J. y M. F. Reiser. "Radiological Evaluation of Patients with Liver Tumors". En Liver Radioembolization with 90Y Microspheres, 15–26. Berlin, Heidelberg: Springer Berlin Heidelberg, 2013. http://dx.doi.org/10.1007/174_2013_810.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

9

Saiz-Mendiguren, Ramón, Javier Arias, Isabel Vivas y José Ignacio Bilbao. "Vascular Anatomy and Its Implication in Radioembolization". En Liver Radioembolization with 90Y Microspheres, 27–40. Berlin, Heidelberg: Springer Berlin Heidelberg, 2013. http://dx.doi.org/10.1007/174_2013_811.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

10

Coldwell, Douglas M., Martin Vyleta y Mahmood Samman. "Treatment of Neuroendocrine Tumors with Selective Internal Radiation Therapy". En Liver Radioembolization with 90Y Microspheres, 151–55. Berlin, Heidelberg: Springer Berlin Heidelberg, 2013. http://dx.doi.org/10.1007/174_2013_812.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Actas de conferencias sobre el tema "Liver radioembolization":

1

Taebi, Amirtahà, Catherine T. Vu y Emilie Roncali. "Prediction of Blood Flow Distribution in Liver Radioembolization Using Convolutional Neural Networks". En ASME 2020 International Mechanical Engineering Congress and Exposition. American Society of Mechanical Engineers, 2020. http://dx.doi.org/10.1115/imece2020-24475.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Resumen

Abstract We have developed a new dosimetry approach, called CFDose, for liver cancer radioembolization based on computational fluid dynamics (CFD) simulation in the hepatic arterial tree. Although CFDose overcomes some of the limitations of the current dosimetry methods such as the unrealistic assumption of homogeneous distribution of yttrium-90 in the liver, it suffers from the expensive computational cost of CFD simulations. To accelerate CFDose, we introduce a deep learning model to predict the blood flow distribution between the liver segments in a patient with hepatocellular carcinoma. The model was trained with the results of CFD simulations under different outlet boundary conditions. The model consisted of convolutional, average pooling and transposed convolution layers. A regression layer with a mean-squared-error loss function was utilized at the network output to estimate the arterial outlet blood flow. The mean-squared error and prediction accuracy were calculated to measure model performance. Results showed that the average difference between the CFD results and predicted flow data was less than 2.45% for all the samples in the test dataset. The proposed model thus estimated the blood flow distribution with high accuracy significantly faster than a CFD simulation. The network output can be used to estimate the yttrium-90 dose distribution in the liver in future studies.

2

Guerra, JM, M. Mustafa, M. Krönke, N. Navab, SG Nekolla, WA Weber y T. Wendler. "Novel Low-Dose CT based Automatic Segmentation and Registration Framework for Liver Radioembolization Planning". En NuklearMedizin 2021 – digital. Georg Thieme Verlag KG, 2021. http://dx.doi.org/10.1055/s-0041-1726852.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

3

Taebi, Amirtaha, Catherine T. Vu y Emilie Roncali. "Estimation of Yttrium-90 Distribution in Liver Radioembolization using Computational Fluid Dynamics and Deep Neural Networks". En 2020 42nd Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC) in conjunction with the 43rd Annual Conference of the Canadian Medical and Biological Engineering Society. IEEE, 2020. http://dx.doi.org/10.1109/embc44109.2020.9176328.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

4

Ghandour, A., X. Li, L. Nasehi, S. Shrikanthan, F. DiFilippo, R. Gurajala y Gordon Mclennan. "Surefire Infusion System versus Non-Surefire Y-90 Radioembolization of Non Resectable Liver Tumors: A Retrospective Review". En Abstracts of 3rd Annual Meeting of the American Society of Digestive Disease Interventions. Thieme Medical Publishers, 2017. http://dx.doi.org/10.1055/s-0037-1603697.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

5

Wang, Chongkai, John Park, Ching Ouyang, Raju Pillai, Jeffrey Longmate, Holly Yin, Christian Avalos et al. "Abstract 528: Radioembolization followed by durvalumab and tremelimumab does not induce immune responses against liver-metastasized MSS colorectal cancer". En Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.am2019-528.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

6

Wang, Chongkai, John Park, Ching Ouyang, Raju Pillai, Jeffrey Longmate, Holly Yin, Christian Avalos et al. "Abstract 528: Radioembolization followed by durvalumab and tremelimumab does not induce immune responses against liver-metastasized MSS colorectal cancer". En Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-528.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.